Ox­ford Bio­med­ica piv­ots by lay­ing off 200 peo­ple, ac­quir­ing ABL Eu­rope amid de­clin­ing to­tal rev­enues

In its bid to be­come a pure-play cell and gene ther­a­py CD­MO, Ox­ford Bio­med­ica is lay­ing off 200 staff mem­bers in the UK and US, as well as ini­ti­at­ing the process to ac­quire ABL Eu­rope to fur­ther lean in­to the vi­ral vec­tor space.

In the face of de­clin­ing over­all rev­enues — by as much as 33% — Ox­ford Bio­med­ica not­ed a sil­ver lin­ing in the in­crease in lentivi­ral vec­tor sales, as per its half-year fi­nan­cial re­sults re­leased Wednes­day. Its pure-play strat­e­gy means it would stop in­ter­nal prod­uct de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER